Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotating sunitinib and everolimus vs sequential sunitinib then everolimus in metastatic clear cell renal cancer
2012-001337-13Phase 2Completed
- Sponsor
- APRO
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sunitinib and everolimus in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by APRO. Primary endpoint: Progression-free survival: sequential arm vs combined two lines in control arm. Started May 2012; status: completed.
02
Drugs
sunitinibeverolimus
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2012-001337-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001337-13.